Osteoporosis in men: Suspect secondary disease first

Cleveland Clinic Journal of Medicine

Volumn 70, Issue 3, 2003, Pages 247-254

  Licata, Angelo ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALENDRONIC ACID; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ESTRADIOL; ETIDRONIC ACID; FLUORIDE SODIUM; GLUCOCORTICOID; GONADOTROPIN ANTAGONIST; GROWTH HORMONE; NONSTEROID ANTIINFLAMMATORY AGENT; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; TESTOSTERONE; THIAZIDE DIURETIC AGENT; THYROXINE; VITAMIN D;

ANAMNESIS; BONE DENSITY; GENDER; HUMAN; LABORATORY TEST; LIFE EXPECTANCY; MALE; OSTEOMALACIA; OSTEOPENIA; OSTEOPOROSIS; REIMBURSEMENT; REVIEW;

EID: 0037366173     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.70.3.247     Document Type: Review

References (55)

1. Diamond TH, Thornley SW, Sekel R, Smerdely P. Hip fracture in elderly men; prognostic factors and outcomes. Med J Aust 1997; 167:412-415.
2. Center JN, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999; 353:878-882.
3. Looker AC, Orwoll ES, Johnston CC, et al. Prevalence of low femoral bone density in older US adults from the NHANES III. J Bone Miner Res 1997; 12:1761-1783.
4. Jaron JJ, Makins NB, Sagreiya K. The microanatomy of trabecular bone loss in normal aging men and women. Clin Orthop 1987; 215:260-271.
5. Portale AA, Lonergan ET, Tanney D, Halloran BP. Aging alters calcium regulation of serum concentration of parathyroid hormone in healthy men. Am J Physiol 1997; 272:139-146.
6. Cahaupey MC, Durr F, Chapui P. Age-related changes in parathyroid hormone and 25 hydroxy cholecalciferol levels. J Gerontol 1983; 38: 19-22.
7. Haden ST, Brown VM, Hurwitz S, Scott J, El-Elajj FG. The effects of Asian gender on parathyroid hormone dynamics. Clin Endocrinol 2000; 52:329-338.
8. Gallagher JC, Kinyamu HK, Fowler SE, Dawson-Hughes B, Dalsky GP, Sherman SS. Calciotropic hormones in bone markers in the elderly. J Bone Miner Res 1998; 13:475-482.
9. Lau KH, Baylink DJ. Vitamin D therapy of osteoporosis: plain vitamin D therapy vs active vitamin D analog (D-hormone) therapy. Calcif Tissue Int 1999; 65:296-306.
10. Orwoll ES, Meier DE. Alterations in calcium, vitamin D in parathyroid hormone physiology in normal men with aging: relationship to the development of senile osteopenia. J Clin Endocrinol Metab 1986; 63:1262-1269.
11. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta analysis. Arch Intern Med 1999; 159:941-955.
12. Zaqqa D, Jackson R. Diagnosis and treatment of glucocorticoid-induced osteoporosis. Cleve Clin J Med 1999; 63:221-230.
13. Tannirandom P, Epstein S. Drug-induced bone loss. Osteoporos Int 2000; 11:637-659.
14. Turner RT. Skeletal response to alcohol. Alcohol Clin Exp Res 2000; 24:1693-1701.
15. Diamond T, Stiel D, Lunzer ML, et al. Ethanol reduces bone formation and may cause osteoporosis. Am J Med 1989; 86:282-288.
16. Valentine F, Snisky CA. Prevention and treatment of osteoporosis in patients with inflammatory bowel disease. Am J Gastroenterol 1999; 94:878-883.
17. Vasquez H, Mazure R, Gonzalez D, et al. Risk of fractures in celiac disease patients: a cross-sectional, case control study. Am J Gastroenterol 2000; 95:183-189.
18. Vleggaar FP, VanBuuren HR, Wolfhagen FH, Schalm SW, Pols HA. Prevention and treatment of osteoporosis in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 1999; 11:617-621.
19. McCaughan W, Feller RB. Osteoporosis in chronic liver disease: pathogenesis, risk factors and management. Dig Dis 1994; 12:223-231.
20. Borghi L, Meschi T, Guerra A, et al. Vertebral mineral content in diet-dependent and diet-independent hypercalciuria. J Urol 1991; 146:1334-1338.
21. Bataille P, Achard JM, Fournier A, et al. Diet, vitamin D, and vertebral mineral density in hypercalciuric calcium stone formers. Kidney Int 1991; 39:1193-1205.
22. Ghazali A, Fuentes V, Desanaint C, et al. Low bone marrow density and peripheral blood monocyte activation profile in calcium stone formers with idiopathic hypercalciuria. J Clin Endocrinol Metab 1997; 82:32-38.
23. Audran M, Legrand E. Hypercalciuria. Joint Bone Spine 2000; 67:509-515.
24. Pietschrnann F, Bleslau NA, Pak CY. Reduced vertebral bone density in hypercalciuric nephrolithiasis. J Bone Miner Res 1992; 7:1383-1388.
25. Domrongkitchaiporn S, Pongsakul C, Stitchantrakul W, et al. Bone mineral density and histology in distal renal tubular acidosis. Kidney Int 2001; 59:1086-1093.
26. Finkelstein JS, Neer RM, Biller B, et al. Osteopenia in men with a history of delayed puberty. N Engl J Med 1992; 226:600-604.
27. Finkelstein JS, Klibanski A, Neer RM. A longitudinal evaluation of bone mineral density in adult men with histories of delayed puberty. J Clin Endocrinol Metab 1996; 81:1152-1155.
28. Berteloni S, Baroncelli G, Battini R, et al. Short-term effective testosterone treatment from reduced bone density in boys with constitutional delay of puberty. J Bone Miner Res 1995; 10:140-148.
29. Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997; 157:439-444.
30. Pecherstorfer M, Seibel MJ, Woitge HW, et al. Bone resorption in multiple myeloma and in monoclonal gamrnopathy of undetermined significance: quantification by urinary pyridinium links of collagen. Blood 1997; 103:743-750.
31. Hoorweg-Numan J, Kardos G, Roos JC, et al. Bone mineral density and markers of bone turnover in young adult survivors of childhood lymphoblastic leukemia. Clin Endocrinol 1999; 50:227-244.
32. Wonke B, Jensen C, Hanslip JJ, et al. Genetic and acquired predisposing factors in treatment of osteoporosis and thalassemia major. J Pediatr Endocrinol Metab 1998; 11:795-801.
33. Goerss JB, Kim CH, Atkinson EJ, et al. Risk of fractures in patients with pernicious anemia. J Bone Miner Res 1992; 7:573-579.
34. Brenton DP, Dow CJ. Homocystinuria and Marfan syndrome: a comparison. J Bone Joint Surg 1972; 54:277-298.
35. Magid D, Pyeritz R, Fishman EK. Musculoskeletal manifestations of the Marfan syndrome. Am J Roentgenol 1990; 155:99-104.
36. Weinstein RS, Whyte MP. Management of adult hypophosphatasia: report of severe and mild cases. Arch Intern Med 1981; 141:727-731.
37. Bischoff H, Freitag P, Jundt G, Steinmann B, Tyndall A, Theiler R. Type 1 osteogenesis imperfecta: diagnostic difficulties. Clin Rheumatol 1999; 18:48-51.
38. Ferrari S, Rizzoli R, Slosman D, Bonjour TP. Familial resemblance for bone mineral mass is expressed before puberty. J Clin Endocrinol Metab 1998; 83:358-361.
39. Lonzer MD, Imrie R, Rogers D, Worley D, Licata A. Effects of heredity, age, weight, puberty, activity, and calcium intake on bone mineral density in children. Clin Pediatr 1996; 35:185-189.
40. Finkelstein JS, Klibanski A, Neer RM, et al. Increase in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1999; 84:1966-1975.
41. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999; 84:1966-1972.
42. Slemenda CW, Longcope C, Zhou L, et al. Sex steroids and bone mass in older men; positive associations with serum estrogens and negative associations with androgens. J Clin Invest 1997; 100:1755-1759.
43. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen receptor gene in a man. N Engl J Med 1994; 331:1059-1061.
44. Chesnut CH 3rd, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis. PROOF Study Group. Am J Med 2000; 109:267-276.
45. Slovik DM, Rosenthal DI, Doppelt SH, et al. Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D. J Bone Miner Res 1986; 1:377-381.
46. Neer RM, Arnaud CD, Zanchetta A et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women osteoporosis. N Engl J Med 2001; 19:1434-1441.
47. Ho KK, Hoffman DM. Aging and growth hormone. Horm Res 1993; 40:80-86.
48. Lissett CA, Shalet SM. Effects of growth hormone on bone and muscle. Growth Horm IGF Res 2000; 10(suppl B):95-101.
49. Baurn BM, Biller BMK, Finkelstein JS, et al. Effect of physiological growth hormone therapy on bone density and body composition in patients with adult onset growth hormone deficiency: a randomized placebo-controlled trial. Ann Intern Med 1996; 125:883-890.
50. Ringe JD, Rovaati LC. Treatment of osteoporosis in men with fluoride alone or in combination with bisphosphonates. Calcif Tissue Int 2001; 69:252-255.
51. Ringe JD, Rovati LC. Treatment of osteoporosis in men with fluoride alone or in combination with bisphosphonates. Calcif Tissue Int 2001; 69:252-255.
52. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343: 604-610.
53. Haguenauer D, Welch V, Shea B, Tugwell P, Adachi JD, Wells G. Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis. Osteoporos Int 2000; 11:727-738.
54. Cortet B, Vasseur J, Grardel B, et al. Management of male osteoporosis. Joint Bone Spine 2001; 68:252-256.
55. Miller PD, Watts NB, Licata AA, et al. Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment. Am J Med 1997; 103:468-476.